EUVIMEDEUVIMED entdecken
Crossref

Single-domain antibodies to reverse the effects of factor Xa inhibitors on coagulation tests

Junxiong Zhao, Ischa Hoornstra, Dana Huskens, Frauke Swieringa, An K Stroobants, Sanna Rijpma, René Heylen, Bas de Laat, Mark Roest

Journal of Thrombosis and Haemostasis · 2026-07 · 24 (7) · 2423-2435

DOI: 10.1016/j.jtha.2026.03.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-07. Verfasst von Junxiong Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Synapse Research Institute, Maastricht, The Netherlands; Department of Biochemistry, Cardiovascular Research Institu…. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Blood Coagulation, Anticoagulation Reversal, Factor Xa. Die Arbeit nennt 35 Literaturangaben. Gefördert von: China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Direct oral anticoagulants (DOACs) interfere with coagulation assays, complicating the diagnosis of thrombophilia and lupus anticoagulants. Single-domain antibodies (sdAbs) may be used to neutralize anticoagulant effects in vitro, thereby restoring physiological coagulation for accurate diagnostic testing. OBJECTIVES: To develop and validate sdAbs specific to DOACs that inhibit factor Xa, specifically edoxaban, apixaban, and rivaroxaban. METHODS: Llama-derived sdAbs specific to DOACs were selected via phage display. To enhance efficacy, bivalent sdAbs were engineered. Both single and bivalent forms were tested in healthy control plasma using various coagulation assays (thrombin generation, prothrombin time [PT], and activated partial thromboplastin time [APTT]), dilute Russell's viper venom time, and international normalized ratio. The ability of these specific sdAbs to reverse the effects of edoxaban, apixaban, and rivaroxaban was also evaluated in plasma samples from patients currently receiving these medications. RESULTS: Antiedoxaban, antiapixaban, and antirivaroxaban sdAbs achieved reversal of edoxaban, apixaban, and rivaroxaban, respectively, as demonstrated by thrombin generation, PT, APTT, dilute Russell's viper venom time, and international normalized ratio assays for both the single and bivalent variants. Specifically, each anti-DOAC sdAb effectively reversed the effects of its respective DOAC on lag time and peak thrombin levels, without overshooting a prothrombotic response. Furthermore, in plasma from edoxaban-, apixaban-, or rivaroxaban-treated patients, the corresponding sdAbs restored both PT and APTT. CONCLUSIONS: We selected and validated sdAbs that specifically reverse the inhibitory effects of edoxaban, apixaban, and rivaroxaban, without procoagulant activity. These low-cost reversal agents work directly on plasma or whole blood without incubation or preanalytical steps. They enable rapid, reliable baseline coagulation testing in patients treated with these DOACs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsBlood CoagulationAnticoagulation ReversalFactor XaHumansBlood Coagulation TestsPyrazolesPyridinesThiazolesPyridonesProthrombin TimePartial Thromboplastin TimeRivaroxabanAnimalsThrombinInternational Normalized Ratio

Stichwörter der Autor:innen

antibodiesanticoagulant reversal agentsanticoagulantscoagulation testssingle-domainthrombin generation assay

Substanzen

Factor Xa InhibitorsapixabanPyrazolesPyridinesThiazolesPyridonesRivaroxabanedoxabanThrombinFactor Xa

Autor:innen und Institutionen

  • Department of Clinical Research, Synapse Research Institute, Maastricht, The Netherlands; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
  • Department of Clinical Research, Synapse Research Institute, Maastricht, The Netherlands.
  • Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Laboratory for Diagnostics, Department of Laboratory Medicine, Radboud University Medical Center…
  • Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Anesthesiology, Katholieke Universiteit Leuven, Leuven, Belgium; Department of Antidotes, Mithridate BV, Genk, Belgium.
  • Department of Clinical Research, Synapse Research Institute, Maastricht, The Netherlands. Electronic address: m.roest@thrombin.org.

Förderung

  • China Scholarship Council

Zitieren

APA

Zhao, J., Hoornstra, I., Huskens, D., Swieringa, F., Stroobants, A. K., Rijpma, S., Heylen, R., de Laat, B., & Roest, M. (2026). Single-domain antibodies to reverse the effects of factor Xa inhibitors on coagulation tests. Journal of Thrombosis and Haemostasis, 24(7), 2423-2435. https://doi.org/10.1016/j.jtha.2026.03.028

Vancouver

Zhao J, Hoornstra I, Huskens D, Swieringa F, Stroobants AK, Rijpma S, et al. Single-domain antibodies to reverse the effects of factor Xa inhibitors on coagulation tests. Journal of Thrombosis and Haemostasis. 2026;24(7):2423-2435. doi:10.1016/j.jtha.2026.03.028

BibTeX
@article{Zhao2026,
  author = {Zhao, Junxiong and Hoornstra, Ischa and Huskens, Dana and Swieringa, Frauke and Stroobants, An K and Rijpma, Sanna and Heylen, René and de Laat, Bas and Roest, Mark},
  title = {Single-domain antibodies to reverse the effects of factor Xa inhibitors on coagulation tests},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {7},
  pages = {2423--2435},
  doi = {10.1016/j.jtha.2026.03.028}
}
Kostenlos starten →